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Abstract
The Kaposi’s sarcoma-associated herpesvirus (KSHV) genome encodes a G protein-coupled receptor (vGPCR). vGPCR is a
ligand-independent, constitutively active signaling molecule that promotes cell growth and proliferation; however, it is not
clear how vGPCR is negatively regulated. We report here that the KSHV K7 small membrane protein interacts with vGPCR
and induces its degradation, thereby dampening vGPCR signaling. K7 interaction with vGPCR is readily detected in
transiently transfected human cells. Mutational analyses reveal that the K7 transmembrane domain is necessary and
sufficient for this interaction. Biochemical and confocal microscopy studies indicate that K7 retains vGPCR in the
endoplasmic reticulum (ER) and induces vGPCR proteasomeal degradation. Indeed, the knockdown of K7 by shRNA-
mediated silencing increases vGPCR protein expression in BCBL-1 cells that are induced for KSHV lytic replication.
Interestingly, K7 expression significantly reduces vGPCR tumorigenicity in nude mice. These findings define a viral factor
that negatively regulates vGPCR protein expression and reveal a post-translational event that modulates GPCR-dependent
transformation and tumorigenicity.
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Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV, also known as
human herpesvirus 8) is believed to be the etiologic agent for
Kaposi’s sarcoma (KS) [1]. KSHV infection is also linked to
primary effusion lymphoma [2] and multicentric Castleman’s
disease, rare lymphoproliferative malignancies of B-cell origin
[3,4]. The KSHV genome encodes over 80 viral polypeptides,
many of which are capable of promoting cell proliferation and/or
modulating host responses, when expressed in gene transfer
experiments (for review see reference [5]). One such gene product
consistently detected in KS lesions is the viral G protein-coupled
receptor (vGPCR, or open reading frame 74) [6,7].
vGPCR is a homolog of the human interleukin-8 receptor and
possesses promiscuous chemokine-binding activity [8]. In tissue
culture, vGPCR expression activates various signaling pathways
and up-regulates the transcription of numerous cellular and viral
genes that encode cytokines, signaling molecules, and transcription
factors that culminate in promoting cell proliferation and
endothelial tube formation [9–15]. Additionally, vGPCR trans-
genic mice developed tumors that resemble human KS lesions
[9,16,17]. Although ligand binding is not required for vGPCR-
mediated signaling, cognate chemokines appear to modulate
vGPCR activity in tissue culture and in mice as well [8,18].
Despite the fact that proliferative and prosurvival activities of
vGPCR have attracted extensive attention in the past, accumu-
lating evidence suggests that tightly regulated expression and
signaling are important for vGPCR function in KSHV infection.
Indeed, over-expression of vGPCR induced cell death in COS-1
cells and constitutive expression of vGPCR was toxic to PEL cells
[6,19]. Furthermore, vGPCR is predominantly translated from a
bicistronic mRNA transcript downstream of K14 (vOX2),
presumably reducing vGPCR protein expression [6,20]. These
observations suggest that KSHV likely has evolved mechanisms to
achieve a temporary expression of the constitutively active vGPCR
during lytic infection. A post-translational degradation is one of
these mechanisms.
Regulated protein degradation is important for a variety of
cellular events including cell cycle, apoptosis, signal transduction,
immune response, and development. Cellular GPCR can be
degraded either by the ubiquitin-proteasome system (UPS) or by
the lysosome. Within the lysomsome, proteins are cleaved by
diverse acidic proteases upon fusion with endosomes or autopha-
gosomes. For UPS substrates, proteins destined for destruction are
tagged with ubiquitin through sequential actions of the E1
activating enzyme, E2 conjugating enzyme, and E3 ligase [21].
Relying on the UPS, the endoplasmic reticulum (ER)-associated
degradation (ERAD) pathway is a major route to remove mis-
folded proteins post-translationally, and plays an essential role for
ER quality control. Indeed, alteration of ERAD pathways has
been implicated in diverse clinical presentations such as neurode-
generation and cystic fibrosis. Furthermore, viruses usurp
components of this pathway to evade host recognition and
possibly modulate other host responses [22–24].
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induces protein degradation of IkB and p53. K7 specifically
interacts with the ubiquitin-associated domain of cellular protein
linking integrin-associated protein and cytoskeleton (PLIC1) and
antagonizes PLIC1, thereby promoting protein degradation [25].
Additionally, K7 was shown to deregulate cellular apoptosis by
targeting Bcl-2 and an ER resident calcium modulating cyclophi-
lin ligand [26,27]. Although these data imply that K7 inhibits
apoptosis to facilitate viral replication, its biological roles in KSHV
infection remain obscure. We report here that K7 interacts with
vGPCR and induces its proteasomeal degradation. The knock-
down of K7 by shRNA-mediated silencing increased vGPCR
protein expression in BCBL-1 cells that are induced for KSHV
lytic replication. Biochemical and confocal microscopy analyses
support that K7 retains vGPCR in the ER, thereby facilitating the
proteasome to degrade vGPCR. Consequently, K7 significantly
reduces vGPCR transformation in vitro and tumorigenicity in
nude mice. These data establish a negative regulation of vGPCR
protein expression and tumorigenicity by KSHV K7.
Results
K7 Interacts with KSHV vGPCR
To understand K7’s functions, we searched for cellular
interacting proteins with K7 as bait using the yeast two-hybrid
screen. One clone contained a partial sequence of a putative G
protein-coupled receptor that encodes its last four transmembrane
(TM) domains. Since the KSHV genome encodes a vGPCR, we
speculated that K7 interacts with vGPCR. To test this possibility,
whole cell lysates of 293T cells transiently transfected with
plasmids expressing vGPCR-Flag and/or K7-V5 were precipitat-
ed with the M2 anti-Flag antibody and precipitates were analyzed
by immunoblot with anti-V5 (K7) antibody. Indeed, K7 was
readily detected in immune complexes containing vGPCR
(Figure 1A, left panels). Notably, vGPCR expression greatly
increases K7 protein expression and the glycosylated form (the
slower migration band) is only detected in the presence of vGPCR.
Reciprocally, vGPCR was also precipitated by anti-V5 (K7)
antibody (Figure 1A, right panels). Of note, the interaction
between K7 and vGPCR was also identified by the yeast two-
hybrid screen with a high throughput approach [28]. To further
characterize the vGPCR-K7 interaction, K7 mutants that contain
various deletions as described in our previous publications [25,26]
were used for a co-immunoprecipitation (co-IP) assay. The
internal hydrophobic region (amino acid 22–74) containing the
putative TM domain was sufficient to interact with vGPCR
(Figure 1B). Unfortunately, K7 mutants lacking the TM domain
were expressed at an undetectable level compared to the wild type
(wt) K7. Thus, we failed to obtain any deletion mutant that no
long interacts with vGPCR. Nevertheless, these data indicate that
K7 interacts with vGPCR and suggest that its predicted TM
domain is important for this interaction.
K7 contains a putative TM domain and vGPCR is a seven-
membrane-spanning protein, therefore we examine whether the
predicted K7 TM domain is necessary for this interaction. The K7
mutant whose putative TM region was replaced by a heterologous
TM from the Saimiri transforming protein C (Stp C), designated
K7TMStp C, was constructed and expressed in 293T cells. We
found that K7TMStp C failed to interact with vGPCR under the
same co-IP conditions (Figure 1C). Of note, K7TMStp C was
expressed and localized to intracellular organelles similarly to the
wt K7 (unpublished data). Furthermore, appending the putative
TM region (amino acids 23–45) of K7 to GFP renders it capable of
binding vGPCR (Figure 1D). Thus, these data collectively support
that K7 interacts with vGPCR and that the putative K7 TM
region is necessary and sufficient for this interaction.
K7 and vGPCR proteins are confined to distinct intracellular
organelles. Particularly, vGPCR was reported to reside primarily
in the trans-Golgi network (TGN) [7], whereas K7 localizes to
both the ER and mitochondrial compartments [26,27]. To
examine the intracellular distribution of vGPCR and K7, indirect
immuno-fluorescence microscopy was performed. To this end,
human lymphoid BJAB and HeLa cells were transfected with
plasmids expressing vGPCR-Flag and K7-V5, and analyzed by
confocal microscopy. In both HeLa and BJAB cells, vGPCR
predominantly localizes to a subcellular structure reminiscent of
the TGN, while K7 distributes throughout the cytoplasm mainly
as punctate vesicles (Figure 2A and 2B). In support of the
interaction between K7 and vGPCR, K7 had an intracellular
staining pattern similar to that of vGPCR in both HeLa and BJAB
cells (Figure 2C). Despite the overall colocalization between K7
and vGPCR, there are some regions that either K7 or vGPCR is
predominant, likely reflecting their distinct intracellular compart-
ments that vGPCR and K7 reside in when they are separately
expressed (Figure 2C, insets of BJAB cells).
Overlapped Expression of vGPCR and K7
The fact that K7 interacts with vGPCR prompted us to
investigate the temporal expression kinetics of K7 and vGPCR in
KSHV lytic replication. Both K7 and vGPCR were reported to be
expressed early during KSHV lytic reactivation and/or de novo
infection [6,7,27,29]; however, the relative temporal expression of
vGPCR and K7 remains unclear. Our interaction study suggests
that vGPCR and K7 are possibly expressed at the same time.
Thus, we examined mRNA levels of vGPCR and K7 by reverse-
transcriptase (RT)-polymerase chain reaction (PCR). The KSHV
latently infected PEL cell lines BCBL-1 (KSHV only) and JSC-1
(KSHV and EBV co-infected) were treated with TPA to induce
KSHV lytic replication. Alternatively, lytic replication was
reactivated by Rta expression that was induced by doxycycline
using the BCBL-1/T-Rex_Rta cell line [30]. RT-PCR analyses
were performed using primers specific for vGPCR, K7, the
polyadenylated nuclear RNA (PAN), and cellular b-actin. When
treated with TPA (20 ng/ml), lytic replication was initiated in both
Author Summary
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the
etiological agent of Kaposi’s sarcoma. KSHV is also found
in primary effusion lymphoma and multicentric Castle-
man’s disease, rare lymphoproliferative diorders associated
with immuno-suppression. The KSHV genome encodes a G
protein-coupled receptor (vGPCR) that is believed to
contribute to the KSHV-associated malignancies. vGPCR
is a ligand-independent, constitutively active signaling
molecule. It is not clear how vGPCR is negatively regulated.
Here, we report that the KSHV small membrane K7 protein
interacts with vGPCR through its putative transmembrane
domain. Interaction with K7 retains vGPCR in the ER and
facilitates its degradation by the proteasome, thereby
reducing vGPCR protein expression. Consequently, K7
significantly reduces vGPCR-mediated transformation in
vitro and tumor formation in nude mice. Our findings
reveal that K7 functions as a viral factor to dampen vGPCR
protein expression and negatively modulate the tumor-
inducing capacity of vGPCR, implying that KSHV has
evolved mechanisms to avoid deleterious effects and to
permit persistent infection within its host.
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PLoS Pathogens | www.plospathogens.org 2 September 2008 | Volume 4 | Issue 9 | e1000157Figure 1. KSHV K7 interacts with vGPCR. (A) K7 interaction with vGPCR by co-IP. (Left) 293T cells were transfected with plasmids containing K7-
V5 and vGPCR-Flag. Proteins precipitated with anti-Flag antibody were resolved by SDS-PAGE and analyzed by immunoblot with anti-V5 (top panel)
and anti-Flag (middle panel) antibodies. WCLs were analyzed by immunoblot with anti-V5 (K7) antibody. Note: the K7 doublet indicates its
glycosylated and unglycosylated forms. (Right) Proteins precipitated with anti-V5 antibody were analyzed by immunoblot with anti-Flag (top panel,
peroxidase-conjugated) and anti-V5 (middle panel) antibodies. WCLs were analyzed by immunoblot with anti-Flag (vGPCR) antibody. H+L, the heavy
and light chains of IgG; IB, immunoblot. (B) The K7 hydrophobic region is sufficient for its interaction with vGPCR. (Top) Diagram shows the structure
of K7 protein and its residue numbers designed for the deletion analysis. Transfection of 293T cells with plasmids as indicated and IP with anti-Flag
antibody were performed. Precipitated proteins were analyzed by immunoblot with anti-V5 (top panel) and anti-Flag (middle panel) antibodies. WCLs
were analyzed with anti-V5 antibody. D3-21, deletion of amino acid 3 to 21; 5K/R, all lysine residues changed to arginine (for more details, please see
[25]). (C) The putative K7 TM domain is necessary for its interaction with vGPCR. The putative K7 TM domain was replaced by the Stp C TM.
Transfection of 293T cells with plasmids as indicated and IP were performed as in (A). Precipitated proteins were analyzed by immunoblot with anti-
Flag (left panel) and anti-V5 (right top panel) antibodies. WCLs were analyzed by immunoblot with anti-V5 (right middle panel) anti-Flag (right
bottom panel) antibodies. TMStpC denotes the K7 mutant that contains a StpC TM domain. To achieve equivalent protein expression, 3-fold more
plasmid containing K7TMStpC than that containing the wt K7 was used for transfection. (D) The putative K7 TM domain is sufficient to interact with
vGPCR. Transfection of 293T cells with plasmids as indicated and IP were performed as in (A). Precipitated proteins were analyzed by immunoblot
with anti-GFP (top panel) and anti-Flag (middle panel) antibodies. WCLs were analyzed by immunoblot with anti-GFP antibody (bottom panel). L, the
light chain of IgG.
doi:10.1371/journal.ppat.1000157.g001
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of PAN transcripts (Figure 3). The residual PAN RNA in
untreated BCBL-1 cells and BCBL-1/T-Rex_Rta cells (lane 3 of
left two sets in Figure 3) are likely due to spontaneous lytic
replication of KSHV or leaky Rta expression in these PEL cells,
respectively. Upon TPA induction, vGPCR transcripts peaked at
72 h, which coincided with the highest mRNA level of K7 in
BCBL-1 cells. Upon Rta expression induced by doxycycline
addition, vGPCR was highly expressed as early as 12 h post
induction and was sustained for more than 24 h (Figure 3, middle
panels), while K7 transcripts gradually increased and peaked at
36 h after TPA induction when vGPCR mRNA started to decline.
This indicates that K7 expression predominantly overlaps with
that of vGPCR in response to the KSHV lytic switch protein, Rta.
Similar results were obtained for TPA-induced JSC-1 cells in
which vGPCR was highly expressed at 12 and 24 h after
treatment. Meanwhile, K7 was highly expressed at 24 h after
induction (Figure 3, right panels). The most abundant lytic
transcript of KSHV, PAN, was significantly induced by TPA and
sustained high transcript levels in BCBL-1 and JSC-1 cells
throughout the entire induction period. This was more pro-
nounced by Rta induction (Figure 3 third panel from top), while
cellular b-actin transcript remained the same. Overall, these data
indicated that K7 and vGPCR are expressed at the same time and
suggest that the interaction between these two molecules is
biologically relevant.
K7 Reduces vGPCR Protein Expression
We have consistently observed that K7 co-expression signifi-
cantly reduces the protein level of vGPCR (Figure 1A and 1B),
suggesting that K7 modulates vGPCR biosynthesis. Because our
previous data implicate K7 in regulating protein degradation [25],
we speculated that K7 induces the degradation of vGPCR. To
examine K7’s effect on vGPCR protein expression, human
endothelial ECV cells were transiently transfected with a plasmid
expressing vGPCR-Flag and increasing amounts of a plasmid
expressing K7-V5. Whole cell lysates were analyzed by immuno-
blot for vGPCR protein expression. The result shows that K7
reduces vGPCR protein in a dose-dependent manner (Figure 4A).
The specificity of K7 is further supported by the observation that
Figure 2. Intracellular localization of vGPCR and K7. Human HeLa and lymphoid BJAB cells were transfected as described in Materials and
Methods. At 16 h after transfection, cells were fixed, permeabilized, and stained with rabbit anti-Flag and mouse anti-V5 antibodies. (A) vGPCR
intracellular localization in human HeLa and BJAB cells. An inset in (A) and (B) represents an image of the other channel. (B) K7 intracellular
localization in human HeLa and BJAB cells. (C) Intracellular co-localization of vGPCR (green) and K7 (red) in human HeLa and BJAB cells. Insets
represent enlarged (3-fold) view of the boxed regions. Representative sections and their overlays (for panels in [C] only) are shown. Scale bar
represents 12.5 mm.
doi:10.1371/journal.ppat.1000157.g002
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with vGPCR, failed to suppress vGPCR protein expression
(Figure 4B).
Previous publications have convincingly shown that vGPCR
activates a number of signaling pathways, leading to the activation
of NF-AT, NF-kB, and AP-1 transcription factors [19,31,32]. To
further correlate K7’s effect on vGPCR protein expression, the
transcription activation of NF-AT, NF-kB, and AP-1 response
elements by vGPCR were measured by luciferase assays in
transiently transfected 293T cells. Consistent with published data,
vGPCR activated NF-kB, NF-AT, and AP-1 transcription factors
by approximately 4, 25, and 4.5 fold, respectively. In contrast, K7
exhibited no effect on the transcription of NF-kB, NF-AT, and
AP-1 (Figure 4C). In agreement with our observation that K7
reduces vGPCR protein, K7 suppressed the transcription
activation by vGPCR to approximately two-fold for NF-kB and
AP-1, and eight-fold for NF-AT, respectively (Figure 4C). These
data indicate that K7 reduces vGPCR protein expression and
mitigates vGPCR-activated downstream signaling.
Although our studies clearly indicate that K7 reduces vGPCR
protein expression, these experiments relied on exogenous protein
expression. To corroborate K7-reduced vGPCR protein expres-
sion during KSHV infection, the shRNA-mediated silencing
experiments were designed to knock down K7 expression and
vGPCR protein level was examined by confocal microscopy. Both
K7 and vGPCR are expressed in the lytic phase during KSHV
infection. Given the fact that K7 open reading frame overlaps with
the transcribed region of PAN (or T1.1), four pairs of short hairpin
RNA (shRNA) molecules targeting the 59 untranslated region of
K7 transcripts were cloned (Figure 4D) and lentiviral particles
were produced in 293T cells. Lentivirus was then used to infect
KSHV-positive BCBL-1 cells that were subsequently treated with
TPA to induce KSHV lytic replication. A scrambled shRNA was
used as a control for all silencing experiments. Among the
shRNAs, K7 shRNA#1 and #3 significantly reduced the level of
K7 transcripts, while these two shRNA molecules had no
discernable alteration on mRNA levels of PAN and vGPCR,
when compared to BCBL-1 cells expressing the scrambled shRNA
(Figure 4D, right panels). Densitometry of RT-PCR products
showed that K7 shRNA#3 and shRNA#1 had a silencing
efficiency of 60% and 50% (Figure 4D). Semi-quantitative PCR
analyses using serial dilution of cDNA templates further support
that K7 transcripts were reduced by 60%–70% (Figure S1).
Notably, the knockdown of K7 did not significantly affect cell
viability after lytic induction, suggesting that additional viral
proteins such as vBcl-2 and vFLIP play a redundant antiapoptotic
role. BCBL-1 cells infected with lentiviruses expressing K7
shRNA#1, shRNA#3, or the scrambled shRNA were induced
with TPA for KSHV lytic replication. At 48 h after induction, cells
were fixed and subjected to confocal microscopy analysis to
examine vGPCR protein level. As shown in Figure 5, the
knockdown of K7 significantly increased vGPCR protein expres-
sion (second and third rows from the top), while the ER resident
protein calreticulin was not affected. The vGPCR-positive cells
increased from 20% in BCBL-1 cells expressing the scrambled
shRNA to 65% in BCBL-1 cells expressing K7 shRNA#3 and
45% in BCBL-1 cells expressing K7 shRNA#1 (Figure 5, middle
panels). Furthermore, merged images clearly indicate the
increased vGPCR protein expression upon K7 knockdown,
because image color shifted from red (calreticulin) in BCBL-1
cells expressing the scrambled shRNA to green (vGPCR) in
BCBL-1 cells expressing K7 shRNA (Figure 5, right panels).
Taken together, these findings support the conclusion that K7
suppresses vGPCR protein expression in tissue culture and in
KSHV lytic infection.
K7 Induces Proteasome-Dependent Degradation of
vGPCR
Our previous publication indicated that K7 induces protein
degradation dependent on the UPS [25]. To investigate the
mechanism by which K7 downregulates vGPCR protein expres-
sion, the half-life of vGPCR was measured by a pulse chase
experiment. Transient transfection of ECV cells expressing
vGPCR or vGPCR and K7 were pulse labeled with [
35S]-
methionine/cysteine (Met/Cys). After extensive washing, ECV
cells were chased with cold medium. Precipitated vGPCR was
quantified by autoradiography and its half-life was calculated. As
shown in Figure 6A, vGPCR has a half-life of about 6.5 h and K7
expression reduced its half-life to approximately 3.4 h, indicating
that K7 promotes vGPCR degradation. Cellular GPCRs are 7-
membrane-spanning proteins that can be degraded through the
lysosome or the UPS [33]. To examine whether K7-induced
vGPCR degradation is dependent on the proteasome or the
lysosome, vGPCR protein stability was examined by a pulse chase
Figure 3. Overlapped expression of K7 and vGPCR during KSHV lytic replication. CBL-1, JSC-1, and BCBL-1/T-Rex_Rta cells were induced
for KSHV lytic replication as described in Materials and Methods. RT-PCR analyses were performed using primers for vGPCR, K7, PAN, and cellular b-
actin. No reverse transcriptase reaction was performed with total RNA of 36 h after treatment of each panel; h, hour after treatment.
doi:10.1371/journal.ppat.1000157.g003
Post-Translational Regulation of KSHV vGPCR by K7
PLoS Pathogens | www.plospathogens.org 5 September 2008 | Volume 4 | Issue 9 | e1000157Figure 4. K7 reduces vGPCR protein expression. (A) K7 reduces vGPCR protein expression in a dose-dependent manner. Human endothelial
ECV cells were transfected with plasmids containing vGPCR-Flag and K7-V5 as indicated. WCLs were analyzed by immunoblot with anti-Flag (vGPCR,
top panel), anti-V5 (K7, middle panel), and anti-tubulin (bottom panel) antibodies. (B) The putative K7 TM domain is necessary for vGPCR
downregulation. Transfection of ECV cells and immunoblot analyses were performed as in (A). Data represents three independent experiments. (C) K7
reduces vGPCR-mediated activation of NF-kB, NF-AT, and AP-1 transcription factors. 293T cells were transfected with reporter plasmid cocktail, and
plasmids containing vGPCR and K7. Luciferase activity normalized against b-galactosidase activity is shown. Error bars denote standard deviation and
data represent three independent experiments. (D) K7 knockdown by shRNA-mediated silencing. (Left Top) The relative genomic locations of K7
coding sequence and the transcribed region of PAN were shown. The numbers indicate the nucleotide position according to a published KSHV
genome sequence (accession number: U75698). Bars represent relative location of sequences base paired with four shRNAs within the 59 untranslated
Post-Translational Regulation of KSHV vGPCR by K7
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proteosome inhibitors (lactacystin and MG132). It was found that
lactacystin and MG132, but not chloroquine, completely blocked
K7-induced vGPCR degradation, indicating that this process
relies on the proteolytic activity of the proteasome (Figure 6B).
Proteasome substrates are often marked with polyubiquitin
chains that facilitate delivery to and subsequent degradation by the
proteasome. To further corroborate the proteasome-dependence
of K7-induced vGPCR degradation, vGPCR ubiquitination was
examined by immunoprecipitation and immunoblot. vGPCR was
precipitated with anti-Flag sepharose and analyzed by immuno-
blot with anti-HA (ubiquitin) antibody. Consistent with the
increased degradation of vGPCR, K7 promoted vGPCR poly-
ubiquitination in the presence of a proteasome inhibitor,
lactacystin (Figure 6C, first panel from left). Recent findings have
shown that K48-linkage ubiquitin chains mediate protein
degradation and K63-linkage ubiquitin chains are involved in
signal transduction. Thus, these ubiquitin mutants were included
in the vGPCR ubiquitination assay. Indeed, the K48R mutant,
but not the K63R mutant, completely abolished vGPCR
ubiquitination induced by K7 (Figure 6C). Of note, the protein
level of precipitated vGPCR and vGPCR in whole cell lysate in
the presence of K7 is significantly lower than vGPCR alone
(Figure 6C, second panel, lanes 2–5, and Figure S2). These data
collectively support the conclusion that K7 increases vGPCR
ubiquitination and promotes its proteasomeal degradation.
K7 Retains vGPCR in the ER to Induce its Degradation
To further define the molecular action of K7 in inducing
vGPCR degradation, vGPCR intracellular localization was
analyzed by confocal microscopy using human HeLa cells.
Consistent with a previous report [7], vGPCR primarily localized
to the TGN stained by anti-TGN46 antibody (Figure 7A). Upon
K7 expression, vGPCR localized to intracellular structures that
resemble the ER and nuclear membrane (Figure 7B), suggesting
that K7 retains vGPCR in the ER compartment. Indeed, HeLa
cells expressing both K7 and vGPCR revealed that these two
proteins colocalized significantly with protein disulfide isomerase
(PDI), an ER resident protein (Figure 7C), supporting the notion
that K7 retains vGPCR in the ER. Furthermore, K7 expression
reduced vGPCR localization in the TGN when intracellular
distribution of vGPCR and K7 was examined in relation to
TGN46 (Figure 7D). These results clearly indicate that K7 retains
vGPCR in the ER and suggest that K7 induces vGPCR
degradation via the ER-associated degradation pathway.
vGPCR and K7 Inhibit Cell Growth in vitro
To examine K7’s effect on vGPCR biological functions,
NIH3T3 cell lines stably expressing K7, vGPCR, and
vGPCR+K7 were established with lentivirus infection. As shown
in Figure 8A, K7 detectably reduced vGPCR protein expression
without affecting its mRNA levels (Figure 8B). Of note, vGPCR
did not further increase K7 protein after treatment by the
Figure 5. Increased vGPCR protein expression by shRNA-mediated K7 knockdown. Lentivirus infection and KSHV lytic replication induced
with TPA were performed as in Figure 4D. Cells were fixed and stained with anti-vGPCR (green) and anti-calreticulin (red) antibodies. vGPCR-positive
and vGPCR-negative cells in 5 randomly selected fields were counted to obtain the percentage shown in the middle panels. For BCBL-1 cells induced
with TPA, images to their right represent enlarged (2.5-fold) view of the boxed regions. Representative sections and their overlays are shown. Scale
bar represents 12.5 mm.
doi:10.1371/journal.ppat.1000157.g005
region of K7. The order of shRNAs on the diagram is: shRNA#2, #3, #1, and #4. (Left Bottom) A diagram shows the experimental design of lentivirus
infection and KSHV lytic replication induced by TPA. (Right) RT-PCR analyses were performed using gene specific primers for K7, b-actin, vGPCR, and
PAN as described in Materials and Methods. Numbers indicate intensity of K7 band measured by densitometry. Data represent two independent
experiments.
doi:10.1371/journal.ppat.1000157.g004
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establish these stable cell lines, we noticed that NIH3T3 cells
expressing vGPCR grow more slowly than the control NIH3T3
cells. In contrast to what was reported [34], NIH3T3/vGPCR
cells had a doubling time of approximately 31 h that is
significantly longer than 22.6 h of NIH3T3/vector cells. RT-
PCR analysis indicated that vGPCR is expressed at similar levels
in NIH3T3, and reactivated BCBL-1 and JSC-1 cells (Figure S3).
This observation rules out the possibility that the inhibitory effect
on cell growth is due to over-expression. Interestingly, K7
expression also increased NIH3T3 doubling time to roughly
28.2 h. Consistent with K7-reduced vGPCR protein expression,
K7 co-expression slightly decreases the doubling time of NIH3T3
cells to 30 h (Figure 8C). Due to K7’s inhibitory effect on cell
growth and vGPCR-increased K7 expression (unpublished data),
the subtle difference in cell growth may be significant. Given the
inhibitory effect of vGPCR on cell growth, we suspect that
NIH3T3 cells expressing higher vGPCR will gradually decrease
when continuously cultured without selection. To test this,
NIH3T3/vGPCR and NIH3T3/vGPCR+K7 cells were passaged
for a week and RT-PCR analyses were performed to assess the
mRNA levels of vGPCR. Indeed, the vGPCR mRNA level
significantly decreased after 1 wk of passage and K7 reduced the
vGPCR loss (Figure 8D). Semi-quantitative RT-PCR and real-
time PCR analyses revealed that the vGPCR mRNA in NIH3T3/
vGPCR+K7 was approximately 5-fold of that in NIH3T3/
vGPCR cells at day 7 (Figure 8E and S4). The rapid loss of
vGPCR transcripts suggests that NIH3T3 cells that lost vGPCR
have a growth advantage.
We and others have shown that K7 inhibits apoptosis induced
by various stress stimulations [25–27]. To examine whether
vGPCR affects K7’s antiapoptotic function, NIH3T3 stable cells
Figure 6. K7 induces proteasome-dependent degradation of vGPCR. (A) K7 reduces the half-life of vGPCR. ECV cells were transfected with
plasmids expressing vGPCR-Flag and K7-V5. Pulse chase, IP, and autoradiography analyses were performed as described in Materials and Methods.
The fully glycosylated vGPCR band was quantified and its half-life was calculated. Data (left panel) represent three independent experiments and
error bars denote standard deviation. (B) K7-induced vGPCR degradation is dependent on the proteasome. Transfection and pulse chase experiments
with ECV cells were performed as described in (A) except cells were harvested at time points as indicated. The numbers at the bottom indicate the
relative intensity (top row) of vGPCR band compared to the initial chase time point and standard deviation (bottom row). Data represent three
independent experiments. Lac: lactacystin (10 mM); MG: MG132 (20 mM); Ch: chloroquine (50 mM). (C) K7 increases vGPCR ubiquitination. NIH3T3/
lenti-puro (Vec) or NIH3T3/lent-vGPCR-Flag (vGPCR) were transfected with plasmids expressing K7-V5 and HA-tagged Ubiquitin (wt), K48R (R48), or
K63R (R63). At 36 h after transfection, cells were treated with lactacystin (20 mM) for 6 h. vGPCR was precipitated with anti-Flag sepharose and eluted
with Flag peptide for immunoblot with anti-HA (ubiquitin, first panel from left), or eluted with loading buffer for immunoblot with anti-Flag (vGPCR,
second panel). WCLs were analyzed by immunoblot with anti-HA (ubiquitin; third panel) and anti-V5 (K7; fourth panel) antibodies. Arrowheads
indicated ubiquitinated vGPCR species (second panel).
doi:10.1371/journal.ppat.1000157.g006
Post-Translational Regulation of KSHV vGPCR by K7
PLoS Pathogens | www.plospathogens.org 8 September 2008 | Volume 4 | Issue 9 | e1000157were stimulated with TNF-a and cyclohexamide and cell viability
was measured by trypan blue staining as described previously [25].
It was found that vGPCR expression had no significant effect on
cell survival upon TNF-a stimulation, while K7 expression
increased cell survival rate by 20% compared to NIH3T3/vector
cells (Figure 8F). Interestingly, vGPCR co-expression with K7
further promotes cell survival rate by approximately 30%,
indicating that vGPCR potentiates K7’s antiapoptotic effect. This
is consistent with our observation that vGPCR increases K7
protein expression (unpublished data). These results indicate that
K7 reduces vGPCR-induced stress and suggest that K7 likely co-
operates with vGPCR to promote cell survival during KSHV lytic
replication.
K7 Negatively Regulates vGPCR Tumorigenicity
In a mouse pathogenesis model, vGPCR is sufficient to induce
tumor formation in nude mice and vGPCR transgenic mice
developed lesions that resemble human KS, suggesting its potential
contribution to KSHV-associated malignancies [17,18,34]. To
assess K7’s effect on vGPCR tumorigenicity, NIH3T3 stable cells
expressing K7, vGPCR, or vGPCR+K7 were mixed with
NIH3T3 cells and colony formation on soft agar was examined.
Similar to the human cytomegalovirus US28 [35], vGPCR-
expressing cells stimulated anchorage-independent growth of
NIH3T3 cells, whereas neither NIH3T3/vector, nor NIH3T3/
K7 cells supported colony formation (Figure 9A). In support of the
observation that K7 suppressed vGPCR protein expression,
NIH3T3/vGPCR+K7 cells formed smaller colonies than
NIH3T3/vGPCR cells (Figure 9A, left panels). Furthermore, K7
expression also reduced the number of colonies from 258 of
NIH3T3/vGPCR to 131 of NIH3T3/vGPCR+K7 (Figure 9A,
right diagram). To further investigate K7’s effect on vGPCR
tumorigenicity in vivo, these stably transfected cells were injected
into nude mice and tumor growth was assessed. Mice injected with
NIH3T3/vGPCR developed visible tumors within two weeks and
all mice harbored tumors after 6 wk. Neither NIH3T3/vector cells
nor NIH3T3/K7 cells induced apparent tumor in nude mice. In
agreement with results from the soft agar assay, K7 significantly
reduced vGPCR capacity to promote tumor growth in nude mice
as shown by the number of mice harboring tumor and tumor
weight (Figure 9B). All four nude mice injected with NIH3T3/
vGPCR developed tumors after 6 wk, whereas only two mice
injected with NIH3T3/vGPCR+K7 developed tumors, which
were substantially smaller (Figure 9B). The mean weight of tumors
Figure 7. K7 retains vGPCR in the ER. (A) vGPCR localizes to the TGN. HeLa cells were transfected with plasmids containing vGPCR-Flag. At 16 h
after transfection, cells were fixed and stained with mouse anti-Flag (vGPCR, green) and sheep anti-TGN46 (red) antibodies. For both (A) and (B),
images at the bottom represent enlarged (3-fold) view of the boxed regions. Representative sections and their overlays are shown. Scale bar
represents 12.5 mm. (B) K7 alters vGPCR intracellular localization. HeLa cells were transfected with plasmids containing vGPCR-Flag and K7-V5, and
fixed as in (A). Cells were stained with rabbit anti-Flag (vGPCR, green) and mouse anti-V5 (K7, red) antibodies. (C) K7 retains vGPCR in the ER. HeLa
cells were transfected with plasmids expressing HA-vGPCR and K7-V5, and fixed as described in (A). Cells were stained with rabbit antibody to protein
disulfide isomerase (PDI, blue) and mouse anti-V5 (K7, red) antibody. After staining with corresponding secondary antibody and extensive washing,
cells were further stained with Alexa 488-conjugated anti-HA antibody (vGPCR, green). Images on the right represent enlarged (3-fold) view of the
boxed regions. Representative sections and their overlays are shown. Scale bar represents 12.5 mm. (D) The intracellular localization of K7 and vGPCR
in relation to the TGN. HeLa cells were transfected with plasmids containing vGPCR-Flag and K7-V5. Cells were fixed and stained with mouse
monoclonal anti-V5 (K7, green) and sheep anti-TGN46 (red) (left panels), or rabbit polyclonal anti-Flag (vGPCR, green) and sheep anti-TGN (red) (right
panels). Representative images and their overlays are shown. Scale bar represents 12.5 mm.
doi:10.1371/journal.ppat.1000157.g007
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lysates of NIH3T3/vector, NIH3T3/vGPCR, NIH3T3/K7, and NIH3T3/vGPCR+K7 were precipitated with anti-HA and immunoblotted with anti-HA
antibody (top panel). For K7 expression, above stable cells were treated with MG132 for 6 h before harvest, K7 was precipitated with anti-Flag and
analyzed by immunoblot with anti-Flag antibody (bottom panel). (B) K7 does not reduce vGPCR mRNA level. The mRNA level of vGPCR in stable cell
lines as described in (A) was analyzed by RT-PCR and b-actin PCR product serves as a loading control. (C) vGPCR and K7 inhibit cell growth. NIH3T3
stable cell lines described in (A) were cultured in complete DMEM containing puromycin (1 mg/ml) and counted at 24 h and 48 h. The doubling time
was measured as derscribed in Materials and Methods. Data represent three independent measurements and error bars denote standard deviation.
(D) K7 reduces the loss of vGPCR transcripts in NIH3T3 cells. NIH3T3 stable cell lines as described in (A) were passaged up to 7 d and RT-PCR analyses
were performed with primers specific for vGPCR, b-actin, and K7. (E) PCR analyses with serial dilution of cDNA templates from NIH3T3/vGPCR and
NIH3T3/vGPCR+K7 were performed using vGPCR-specific primers. The ratio denotes fold of serial dilutions. (F) The effect of vGPCR and K7 on
apoptosis. NIH3T3 stable cell lines were treated with TNF-a (5 ng/ml) and CHX (1 mg/ml) for 24 h; cell viability measured by trypan blue staining is
shown. Data represent 3 independent experiments, and error bars denote standard deviation; *p,0.03 relative to NIH3T3/vector cells as calculated
by Student’s t-test.
doi:10.1371/journal.ppat.1000157.g008
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higher than that of tumors derived from NIH3T3/vGPCR+K7
cells (Figure 9B and unpublished data). Interestingly, we found
that K7 transcripts were expressed at a higher level in the smaller
tumor than the bigger tumor, suggesting that K7 inhibits the
vGPCR-dependent tumor growth in vivo (Figure 9C). This result
Figure 9. K7 negatively regulates vGPCR tumorigenicity. (A) K7 reduces vGPCR activity to stimulate anchorage-independent growth of
NIH3T3 cells. Colonies under microscope were photographed (left panels, 46) or counted (right graph) after a 2-wk incubation. Data represent 3
independent experiments. Error bars denote standard deviation; *p,0.02 relative to NIH3T3/vGPCR cells as calculated by Student’s t-test. (B) K7
reduces vGPCR tumorigenicity in nude mice. Cells were injected into nude mice subcutaneously, and mice were killed and photographed (left panel)
6 wk later. Tumor weight was measured (right graph). The numbers in parenthesis indicate the number of mice developed tumor among 4 tested
animals. Arrows indicate location of tumor and data represent 4 independent measurements for each group. (C) vGPCR and K7 expression in tumors.
RT-PCR analyses were performed as described in Materials and Methods using primers specific for vGPCR, K7, and cellular b-actin. PCR products
resolved on agarose gel were photographed. B, the bigger tumor; S, the smaller tumor; Pos, a positive control of K7.
doi:10.1371/journal.ppat.1000157.g009
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vGPCR tumorigenicity (Figure 9B). In contrast, the vGPCR
transcript was expressed more abundantly in tumors derived from
NIH3T3/vGPCR+K7 cells than those derived from NIH3T3/
vGPCR cells (Figure 9C). This likely represents the relative
expression of vGPCR in stable NIH3T3 cells before mice
injection. Overall, K7 negatively regulates vGPCR tumorigenicity
in vitro by a soft agar assay and in vivo in nude mice.
Discussion
We report here that KSHV K7 interacts specifically with
vGPCR and induces the rapid degradation of vGPCR, thereby
reducing vGPCR protein expression. The putative K7 TM
domain is necessary and sufficient for its interaction with vGPCR,
indicating a specific interaction between vGPCR and K7.
However, the K7/vGPCR interaction may involve multiple
residues within the putative TM domain of K7 because further
mutational analyses within this domain failed to identify critical
residues that are essential for this interaction (unpublished data).
Alternatively, additional cellular components such as membrane
proteins or lipids could be involved, as our co-IP procedure does
not exclude this possibility. Nevertheless, these data support the
conclusion that K7 interacts specifically with vGPCR.
We have previously shown that K7 antagonizes cellular PLIC1,
a factor that inhibits proteasome-mediated protein degradation,
and induces rapid degradation of p53 and IkB [25]. Our current
study enlists vGPCR as an additional proteasome substrate whose
degradation is accelerated by K7. The specificity of K7-induced
degradation appears to be derived from an interaction with either
a proteasome substrate such as vGPCR or a key component of the
UPS pathway such as PLIC1. It is possible that binding of K7 to
cellular PLIC1 also contributes to K7-dependent reduced
expression of vGPCR, given that PLIC1 has been shown to
promote protein expression of multiple transmembrane proteins
[36,37]. Indeed, we have observed that PLIC1 overexpression
increases vGPCR protein, while the knockdown of PLIC1 by
shRNA-mediated silencing greatly reduces vGPCR protein
expression. These data indicate that PLIC1 is a positive regulator
for vGPCR expression (unpublished data). Future experiments will
determine whether K7 binding to PLIC1 is sufficient for
suppressing vGPCR protein expression.
Confocal microscopy analyses and biochemical assays examining
vGPCR protein degradation support the conclusion that K7 retains
vGPCR in the ER and allows vGPCR to be removed by the
proteasome. The rapid degradation of vGPCR induced by K7 also
correlates with increased ubiquitination upon treatment with a
proteasome inhibitor.vGPCRappearstocarrypolyubiquitinchains
and K7-induced polyubiquitination of vGPCR is specifically
inhibited by the K48R ubiquitin mutant, but not by the K63R
ubiquitin mutant (Figure 6C). Interestingly, the K63R mutant
significantly increased unmodified- as well as ubiquitinated-vGPCR
protein. This is likely due to the inhibitory effect of K63R ubiquitin
on vGPCR signaling that is presumably coupled to vGPCR
degradation. For example, the K63R mutant may inhibit signaling
downstream vGPCR such as NF-kB activation, therefore stabilizing
vGPCR. Alternatively, vGPCR polyubiquitin chains may contain a
mixture of K63- and K48-linkages. The fact that the K48R mutant
abolished, while the K63R mutant increased vGPCR ubiquitina-
tion suggests that K48-linkage is necessary to initiate ubiquitination,
whereas K63-linkage is important for degradation. These intriguing
possibilities are not mutually exclusive and require further
experimental investigation. Our data, however, do not exclude
the possibility that vGPCR undergoes ubquitination-independent
proteasomeal degradation. In transfected cells, K7 consistently
altered vGPCR intracellular distribution, showing a more diffused
ER/nuclear membrane pattern that was confirmed by staining with
anti-PDI antibody. This observation suggests that K7 retains
vGPCR in the ER in order to induce vGPCR degradation. This
also implies that K7 likely engages the ERAD pathway to facilitate
vGPCR degradation in similar ways employed by human
cytomegalovirus US11 and murine c-herpesvirus 68 mK3
[23,24,38,39]. Future experiments will be directed to test whether
K7-induced protein degradation is dependent on any critical
components of the ERAD pathway.
Interaction with K7was found to reducevGPCR protein,thereby
dampening vGPCR-mediated signaling. Both vGPCR and K7 are
expressed during KSHV lytic replication and it appears that K7 and
vGPCR share an identical or overlapped expression profile. The
observation that the K7 transcript peaks at a later time point than
the vGPCR transcript raises the possibility that K7 serves as a
negative regulatory factor to shut off vGPCR protein during KSHV
lytic infection. Indeed, the knockdown of K7 by shRNA-mediated
silencing increased vGPCR protein without altering vGPCR
transcription level in BCBL-1 cells that are induced for KSHV lytic
replication (Figure 5). Interestingly, K7 protein expression was
substantially increased when co-expressed with vGPCR (unpub-
lished data), revealing a negative feedback loop that culminates in
dampening vGPCR protein expression. These observations are
consistent with the notion that diverse regulatory mechanisms
operate to achieve a temporary expression of vGPCR in KSHV
infection. In addition to the K7-reduced vGPCR expression, known
mechanisms also include the bicistronic translation and the vMIP-
mediated regulation [18,40]. Interestingly, modulation by its
cognate chemokines is important for vGPCR tumorigenicity in
transgenic mice [18]. Our findings that K7 interacts with vGPCR
and directs it for proteasome-mediated degradation further support
the notion that KSHV has evolved intricate mechanisms to regulate
vGPCR activity. Additionally, K7 expression provides antiapoptotic
activityunder various conditions[25–27] and vGPCR co-expression
potentiates K7’s antiapoptotic activity (Figure 8F). This implies that
K7 can cooperate with vGPCR in the tumorigenesis of KSHV
infection, analogous to the paradigm in which Bcl-2 cooperates with
c-myc [41]. However, our transformation assay in vitro and tumor
growth in nude mice ruled out this possibility. Together with the
biscitronic translation and modulation by vMIP chemokines,
vGPCR downregulation by K7 raises an intriguing speculation that
KSHV has evolved these mechanisms to monitor vGPCR
pathogenicity, permitting a persistent infection within its host.
K7 expression suppressed vGPCR transformation on soft agar
assay and more pronouncedly reduced vGPCR tumorigenicity in
nude mice. Although K7 reduced vGPCR protein expression by
approximately two-fold (Figures 6A and 8A), it was found that K7
inhibited vGPCR tumorigenicity by more than 8-fold (Figure 9B).
This suggests that additional mechanisms, other than reduced protein
expression, may contribute to K7’s effect on vGPCR tumorigenicity.
One likely mechanism is a K7-dependent retention of vGPCR in the
ER, given that vGPCR predominantly localizes to the TGN and cell
surface under normal circumstances. Conceivably, vGPCR functions
in the TGN and on the cell surface are abolished by K7 expression.
Interestingly, we have found that vGPCR is tyrosine sulfated in the
TGN and tyrosine sulfation is important for vGPCR tumorigenicity
(unpublished data).In addition to tyrosine sulfation, post-translational
modifications in the ER (such as ubiquitination and glycosylation)
altered by K7 may cause impaired vGPCR signaling and
tumorigenicity. These mechanisms are not mutually exclusive and
warrant further investigations of post-translational events underlying
vGPCR tumorigenicity.
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stress in mammalian cells including KSHV infected PEL cells
[6,13]. Indeed, our vGPCR-expressing NIH3T3 cells have a
longer doubling time than control NIH3T3/vector cells
(Figure 8C). Furthermore, NIH3T3/vGPCR cells gradually lost
vGPCR expression when continuously passaged in vitro, suggest-
ing that NIH3T3 cells gain a growth advantage by reducing
vGPCR expression. Indeed, K7 alleviated vGPCR-mediated
inhibition of NIH3T3 growth and the rate of vGPCR transcript
loss (Figure 8C–8E). In contrast, vGPCR expression was necessary
for tumorigenicity in nude mice, and K7-reduced vGPCR
expression correlated with less transformation in vitro and
tumorigenicity in vivo (Figure 9A and 9B). Interestingly, the
endothelial progenitor cell line containing Bac36 (a KSHV
Bacmid) behaves similarly to NIH3T3/vGPCR cells, demonstrat-
ing reduced cell growth in vitro and increased tumor formation in
vivo [42]. The seemingly paradox between in vitro stress and in
vivo tumorigenicity may be explained by a paracrine mechanism
supported by accumulating studies [9,43,44]. In fact, vGPCR-
induced tumor formation is highly dependent on growth factors
and chemokines that stimulate the angio-proliferation of neigh-
boring cells [43,44]. In KS lesions, vGPCR expressing cells
presumably stimulate the proliferation of spindle cells that are
latently infected by KSHV. The fact that slower growth of
NIH3T3 stable cell lines in vitro correlates with higher
tumorigenicity in vivo suggests that the nude mice model primarily
assesses the paracrine function of vGPCR. This is also supported
by our in vitro transformation assay where the proliferation of
regular NIH3T3 cells was examined in the presence of NIH3T3/
vGPCR cells (Figure 9A). Additionally, it is not unprecedented
that oncogenic proteins exploit cellular stress responses to induce
tumor formation. Perhaps, these stress responses represent various
barriers that oncogenesis has to overcome. For example, H-RAS
triggers the ER-associated unfolded protein response, cellular
senescence and sensitizes cells to apoptosis [45,46]. Similarly, the
myc-mediated stress is overcome by Bcl-2 expression [41]. Taken
together, the fact that the stress in tissue culture accompanies the
tumorigenicity in vivo for many oncogenic proteins suggests that
the stress response may serve as an indicator for tumorigenicity in
vivo. Similar to vGPCR, K7 also reduces NIH3T3 growth and it
will be interesting to examine K7’s tumorigenicity in nude mice.
All members of the beta- and gamma-herpesvirus family encode
up to four GPCRs in their genomes. Some of them have been
shown to constitutively activate signaling events downstream of
various G proteins (for review see [47]). Although it was
demonstrated that KSHV vGPCR can be uncoupled from
downstream signal activation by overexpressed G protein-coupled
receptor kinase 5 and arrestins [48], it is largely unknown how
these unconventional viral GPCRs are differentially regulated as
opposed to cellular GPCRs under normal physiological conditions.
This study established an example of post-translational regulation
of vGPCR pathogenicity by which a viral factor-induced
degradation greatly influences its tumorigenicity. Similar regula-
tory mechanisms may exist for other viral GPCRs of herpesviruses.
Therefore, viral factors that modulate these viral GPCRs likely
have a profound effect on various biological activities during
herpesvirus infection.
Materials and Methods
Plasmids
Unless specified, all constructs were derived from pcDNA5/
FRT/TO (Invitrogen). A DNA fragment corresponding to the
KSHV vGPCR was amplified from BCBL-1 genomic DNA by
polymerase chain reaction (PCR) and cloned into pcDNA5/FRT/
TO between BamHI and XhoI. For protein expression, either the
HA epitope or the Flag epitope was inserted upstream or
downstream of vGPCR coding sequence, respectively. Plasmids
expressing wild-type and mutant K7 polypeptides were described
in previous publications [25,26]. For lentiviral expression, K7-Flag
was cloned into pCDH-EF-puro (System Bioscience) between
EcoRI and BamHI. HA-vGPCR was digested with EcoRI and
BglII, and ligated to pCDH-EF-puro or pCDH-EF-CopGFP that
was digested with EcoRI and BamHI. To generate the K7TMStpC,
the K7 transmembrane (TM) domain was replaced with a
heterologous TM segment of Stp C by PCR-based mutagenesis
using overlapping PCR primers. All constructs were sequenced for
verification.
For the shRNA-mediated knockdown of K7, four pairs of
synthetic DNA oligos were annealed and cloned into pLKO.1
(Sigma) that was digested with AgeI and EcoRI. The pLKO.1
expressing the scrambled shRNA was purchased from Sigma.
Plasmids expressing HA-tagged wt and mutant ubiquitin were a
kindly gift from Dr. James Z.J. Chen (UT Southwestern).
Cell Culture and Transfection
HEK293T (293T), HeLa, and NIH3T3 cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum, 5 mM L-glutamine, 100 U/ml penicillin, and
100 mg/ml streptomycin. BJAB, JSC-1, BCBL-1, and BCBL-1/T-
Rex_Rta cells were grown in RPMI 1640 supplemented with 10%
fetal calf serum, 5 mM L-glutamine, 100 U/ml penicillin, and
100 mg/ml streptomycin. BCBL-1 cells were treated with phorbol-
12-teradecanoate-13-acetate (TPA, 20 ng/ml) to induce lytic
replication. HeLa cells were transfected with Fugene 6 (Roche),
293T cells were transfected with calcium phosphate (Clontech),
ECV cells were transfected with lipofectamine (Invitrogen), and
BJAB cells were transfected with electroporation at 220 V/
975 mF. The stable BCBL-1/T-Rex_Rta inducible cell line was
maintained and induced as previously described [30].
Immunoprecipitation and Immunoblot
Immunoprecipitation and immuno-blot analyses were per-
formed as previously described [26]. Immunoblot detection was
performed with anti-V5 antibody (1:5000, Invitrogen), anti-Flag
M2 antibody (1:5000, Sigma), anti-HA (1:2000, Covance), anti-
tubulin (1:250, Santa Cruz), or anti-actin (1:30,000, Abcam).
Proteins were visualized with chemical luminescent detection
reagent (Pierce) and a Fuji LAS-3000 camera.
Reverse Transcriptase (RT)-PCR
One million KSHV latently infected BCBL-1 or JSC-1 cells
were treated with either TPA (20 ng/ml) to induce viral lytic
replication and harvested at various time points. Alternatively,
KSHV lytic replication was induced in BCBL-1/T-Rex_Rta
stable cells with doxycline (1 mg/ml). Total RNA was extracted
with RNAeasy column (Qiagen, CA) and digested with DNase I at
37uC for 1 h. After phenol/chloroform extraction, 1 mg of total
RNA was used for first-strand cDNA synthesis using an oligo(dT)
primer. Then, 1 ml of cDNA was added to 19 ml of PCR mixture
and gene of interest was amplified using specific primers. PCR
products were resolved on agarose gel and photographed. For
each gene of interest, dilution of original cDNA and cycle number
were determined to warrant that PCR products were generated
within the linear range of PCR reaction. Total RNA from tumor
tissues was extracted with triazol (Invitrogen, CA) and ethanol
precipitation as previously described.
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Transiently transfected ECV cells were pulse labeled with
35S-
methionine/cysteine (Met/Cys) for 30 min. After extensive
washing with phosphate buffered saline (137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4), cells were
chased with cold medium up to 16 h. At various time points, cells
were harvested, washed with cold PBS, resuspended in RIPA
buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 0.5% sodium
deoxycholate, 0.1% SDS, 1% NP40, 5 mM EDTA/EGTA), and
lysed by passing through 26-G syringe for 15 times. Centrifuged
supernatant was pre-cleared with protein A/G agarose and mixed
with 2 mg of anti-Flag M2 antibody. Incubation was carried out at
4uC for 4–6 h. Protein A/G agarose was added and incubation
was further extended for 90 min. After extensive washing with
RIPA buffer, precipitated proteins were resolved by SDS-PAGE
and analyzed by autoradiography. The relative intensity of a
selected protein band was quantified and its half-life was
calculated. When vGPCR degradation route was investigated,
20 mM of lactacystin and MG132 (proteasome inhibitors) or
50 mM of chloriquine (a lysosome inhibitor) was added during the
chase period. IP and autoradiography were performed similarly.
Luciferase Reporter Assay
The reporter cocktail consists of plasmids expressing fire fly
luciferase (50 ng/ml) and b-galactosidase (100 ng/ml). While b-
galactosidase expression is driven by a housekeeping glucopho-
sphokinase promoter, the expression of fire fly luciferase is under
control of response elements of NF-kB, NF-AT, and AP-1
transcription factor. 293T cells were transiently transfected with
2.5 ml of reporter cocktail, and 200 ng of plasmids expressing
vGPCR and K7. For each transfection, the total amount of
plasmid was balanced with an empty vector (pcDNA5/FRT/TO).
At 36 h after transfection, cells were harvested and lysed on ice.
Centrifuged supernatant was used to measure luciferase and b-
galactosidase activity according to manufacturer’s protocol
(Promega).
Apoptosis Assay
NIH3T3 stable cells were treated with vehicle (DMSO),
cyclohexamide (CHX, 1 mg/ml), or TNF-a (5 ng/ml) plus CHX
(1 mg/ml) for 24 hours. Cells were harvested and live cells were
scored by trypan blue staining as previously described [25]. Viable
cells treated with drugs divided by viable cells treated by DMSO
was used to obtain cell viability in percentage.
Immunofluorescence Microscopy
BJAB, HeLa, or BCBL-1 cells were fixed with paraformalde-
hyde and permeabilized with Triton X-100 (0.2% in PBS). After
stained with primary and secondary antibodies, cells were
analyzed by immunofluorescence microscopy as previously
described [26,49]. vGPCR in BCBL-1 cells was detected with a
gift rabbit polyclonal antibody provided by Dr. Gary Hayward [7].
For commercial antibodies, mouse monoclonal anti-Flag antibody
(1:1500), rabbit polyclonal anti-Flag antibody (1:400, Sigma),
mouse monoclonal anti-V5 antibody (1:500, Invitrogen), sheep
anti-TGN46 (1:200, Serotec), rabbit anti-PDI (1:200, Calbiochem)
were used. All conjugated secondary antibodies were obtained
from Molecular Probes and diluted at 1:1000 (Alexa 488-
conjugated) or 1:500 (Alexa 568 or Alexa 647-conjugated).
Knockdown of K7 by shRNA-mediated silencing
Four shRNA seuquences were designed using Dharmacon
software and cloned into pLKO.1. These sequences are: 59
TCATCCGTATTGTGTATAT 39;5 9 CATCGTGAGTTGGT-
TAATA 39;5 9 TGGCTACTCTGCTCGATTA 39;5 9 TGAAG-
GATGATGTTAATGA 39. Together with packaging plasmids
DR8.9 and VSV-G, pLKO.1 plasmids expressing various K7
shRNA molecules were transfected into 293T cells with Fugene 6
(Roche). Lentivirus expressing the scrambled shRNA was
produced similarly. Filtered lentivirus was used to infect BCBL-1
cells at 20 MOI in medium containing 10 mg/ml polybrene. To
increase infection efficiency, cells were centrifuged at 1,800 rpm,
30uC for 1 h and incubation was further extended for up to 12 h.
The infection was repeated once and cells were selected with
puromycin at 1 mg/ml. At 48 h later, BCBL-1 cells were treated
with TPA (20 ng/ml) to induce KSHV lytic replication.
Cell Growth and Soft Agar Assay
NIH3T3 cells were infected with lentiviruses to establish stable
cell lines expressing K7 with puromycin selection. Then,
NIH3T3/puro and NIH3T3/K7 cells were further infected with
lentivirus expressing GFP or vGPCR. This lentiviral infection was
repeated once to obtain stable cells expressing K7, vGPCR, or
vGPCR and K7. Cells were cultured in complete DMEM medium
containing puromycin (1 mg/ml). To measure the doubling time,
2610
5 cells were plated and cells were counted at 24 h and 48 h
later. The soft agar assay was performed as described by Liang et
al [50]. Stable NIH3T3 cells (5610
4) were mixed with 1610
5
normal NIH3T3 cells and cultured for two weeks in regular
culture medium without puromycin.
Tumor Formation In Vivo
All animal experiments were performed according to the
National Institutes of Health principles of laboratory animal care
and approved by the University of Texas Southwestern Medical
Center. Stable NIH3T3 cells (3610
6/site) expressing GFP, K7,
vGPCR, or vGPCR and K7 were injected subcutaneously into the
flanks of 6- to 8-wk-old mice (athymic, nu/nu, Jackson Laboratory).
Supporting Information
Figure S1 Knockdown of K7 During KSHV Lytic Reactivation.
(A) The knockdown efficiency of K7 by shRNA-mediated
silencing. BCBL-1 cells were infected with lentivirus and induced
for lytic reactivation as diagrammed in Figure 4D. RT-PCR
analyses were performed with serial dilution of cDNA template
(shown in Figure 4D) as indicated by the ratio. (B) K7 knockdown
on cell viability in KSHV lytic reactivated cells. Lentivirus
infection and lytic reactivation were performed as in (A). Cells
were harvested and cell viability was assessed by trypan blue
staining.
Found at: doi:10.1371/journal.ppat.1000157.s001 (0.12 MB TIF)
Figure S2 Reduced Expression of vGPCR by K7 Mutants and
Lactacystin Treatment. (A) Glycosylation and ubiquitination are
dispensable for K7’s ability to reduce vGPCR protein expression.
Whole cell lysates of ECV cells transfected with plasmids
containing vGPCR and K7 as indicated were analyzed by
immunoblot with anti-Flag (vGPCR, top panel), anti-actin (middle
panel), and anti-V5 (K7, bottom panel). Of note, the K7(5K.R)
and K7(N108Q) carry 6xHIS downstream of the V5 epitope that
reduces their detection by immunoblot. Ub, ubiquitinated K7; gly,
glycosylated K7. (B) The effect of lactacystin treatment on K7-
reduced vGPCR expression. Human ECV cells were transfected
with plasmids containing vGPCR or K7 and treated for 6 h with
DMSO or lactacystin (20 mM). Whole cell lysates were analyzed by
immunoblot with anti-Flag (vGPCR, top panel), anti-actin (middle
panel), and anti-V5 (bottom panel).
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Figure S3 Relative Expression Levels of vGPCR in Reactivated
BCBL-1 Cells and NIH3T3 Stable Cells. Total RNA was
extracted and RT-PCR analyses were performed as described in
Materials and Methods using gene specific primers to vGPCR and
b-actin. BCBL-1 cells were induced for lytic reactivation by TPA
(20 ng/ml, 48 h) or BCBL-1/T-Rex_Rta cells were treated with
doxycycline (1 mg/ml, 72 h) before harvest. No PCR product was
etected for controls without RT (data not shown). The primers for
b-actin locate within a highly conserved region of the human and
mouse b-actin gene.
Found at: doi:10.1371/journal.ppat.1000157.s003 (0.11 MB TIF)
Figure S4 vGPCR mRNA Levels in NIH3T3 Stable Cells by
Real-Time PCR. The primers were designed using Primer Express
v1.5 (Applied Biosystems). The efficiency and specificity of primers
were validated and the real-time PCR using cDNA was performed
with an ABI 7500 sequence detection system (Applied Biosystems).
The vGPCR mRNA level at day 7 was arbitrarily set as 1. Data
represent three independent experiments and error bars denote
standard deviation.
Found at: doi:10.1371/journal.ppat.1000157.s004 (0.05 MB TIF)
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